104 related articles for article (PubMed ID: 20561353)
1. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications.
Santagostino E
Haemophilia; 2010 Jul; 16 Suppl 6():13-7. PubMed ID: 20561353
[No Abstract] [Full Text] [Related]
2. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
3. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
4. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
[TBL] [Abstract][Full Text] [Related]
6. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
Siegmund B; Richter H; Pollmann H
Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
8. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
Ludwig E; Lechner K
Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
[No Abstract] [Full Text] [Related]
9. Dose and response in haemophilia--optimization of factor replacement therapy.
Srivastava A
Br J Haematol; 2004 Oct; 127(1):12-25. PubMed ID: 15384973
[TBL] [Abstract][Full Text] [Related]
10. Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.
Barnbrock A; Heller C; Königs C; Budde U; Schwabe D
Haemophilia; 2016 Sep; 22(5):e437-9. PubMed ID: 27353656
[No Abstract] [Full Text] [Related]
11. Central venous access catheters in children with haemophilia.
Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
[TBL] [Abstract][Full Text] [Related]
12. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
Berntorp E; Keeling D; Makris M; Tagliaferri A; Male C; Mauser-Bunschoten EP; Musso R; Roca CA; Hassoun A; Kollmer C; Charnigo R; Baumann J; Rendo P
Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
[TBL] [Abstract][Full Text] [Related]
13. Secondary prophylaxis in adolescent and adult haemophiliacs.
Tagliaferri A; Di Perna C; Rivolta GF
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s17-20. PubMed ID: 19105505
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis in children with hemophilia: is it the optimal treatment?
Lusher JM
Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
[No Abstract] [Full Text] [Related]
15. The international factor IX treatment network survey.
Berntorp E; Shapiro AD; Waters J; Astermark J;
Haemophilia; 2012 May; 18(3):e60-2. PubMed ID: 22404549
[No Abstract] [Full Text] [Related]
16. Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B.
Levine PH
N Engl J Med; 1974 Dec; 291(26):1381-4. PubMed ID: 4427642
[No Abstract] [Full Text] [Related]
17. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Aledort LM
Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
[TBL] [Abstract][Full Text] [Related]
18. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
[TBL] [Abstract][Full Text] [Related]
19. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
Ullman M; Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
[TBL] [Abstract][Full Text] [Related]
20. [A controlled study of long-term treatment of haemophilia B on an out-patient basis (author's transl)].
Schimpf K; Baumann P
Dtsch Med Wochenschr; 1976 Feb; 101(7):233-8. PubMed ID: 1248406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
